Please assess the completion status of the following clinical trial:

Trial Title: R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of histologically confirmed classical Hodgkin lymphoma (cHL)~* Limited-stage disease defined as stage I or IIA with no areas of bulky disease~* Measurable disease according to the Cheson criteria~* Age \>=18 years~* Adequate bone marrow reserve (ANC \>= 1,500/uL, Platelet \> 100,000/uL)~* LVEF \>= 50% by MUGA scan or echocardiogram~* Serum creatinine \< 2 mg/dl, serum bilirubin \< 2 mg/dl, AST or ALT \<2x ULN~* Bi-dimensionally measurable disease~* Use of effective means of contraception~* Signed informed consent form~Exclusion Criteria:~* Lymphocyte predominant HL~* Prior chemotherapy or radiation therapy~* Severe pulmonary disease as judged by the PI including COPD and asthma~* Presence of CNS lymphoma~* Concomitant malignancies or previous malignancies (exception made for adequately treated basal or squamous cell carcinoma of the skin)~* Active infection requiring treatment with intravenous therapy~* Known HIV infection~* Active hepatitis B or C~* Pregnancy or lactation and women of child bearing age who are not practicing adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A (Type: EXPERIMENTAL): Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
- ARM B (Type: ACTIVE_COMPARATOR): ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).